Detalles de la búsqueda
1.
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
J Virol
; 93(11)2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30918073
2.
Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
J Virol
; 88(10): 5242-55, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24574403
3.
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination.
Clin Transl Immunology
; 11(5): e1392, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35573979
4.
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer.
Mol Ther Oncolytics
; 19: 57-66, 2020 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33072863
5.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-ßGal and MVA-MUC1 (TG4010) in a murine tumor model.
Hum Vaccin Immunother
; 14(1): 140-145, 2018 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28925793
6.
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
Vaccine
; 35(4): 577-585, 2017 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28012777
Resultados
1 -
6
de 6
1
Próxima >
>>